Defitelio is a medication formulated as an intravenous injection containing defibrotide sodium, primarily used for managing hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT). VOD is a serious condition characterized by the obstruction of small veins in the liver, which may lead to hepatic dysfunction and multi-organ failure. This drug is particularly crucial in cases where VOD is accompanied by renal or pulmonary complications.

The mechanism of action of Defitelio is not fully elucidated in the document; however, it is known to exert its therapeutic effects by improving endothelial function and protecting vascular integrity, making it a vital intervention in critically ill post-transplant patients. The treatment protocol typically involves administering a 6.25 mg/kg dose every 6 hours through a 2-hour intravenous infusion for a minimum of 21 days, with continued treatment if symptoms persist.